Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 07, 2023 16:30 ET
|
Gritstone bio
EMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio’s Next Generation COVID-19 Vaccine
October 11, 2023 07:10 ET
|
Gritstone bio
-- High neutralizing antibody (nAb) responses sustained through at least 12 months, highlighting potential for durable clinical protection -- -- T cell responses to Spike plus other viral targets...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2023 07:00 ET
|
Gritstone bio
EMERYVILLE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio Announces Presentations from Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19 at IDWeek 2023
October 04, 2023 16:05 ET
|
Gritstone bio
EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
September 27, 2023 16:01 ET
|
Gritstone bio
Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433M
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 13, 2023 16:30 ET
|
Gritstone bio
EMERYVILLE, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio to Participate in Upcoming Investor Conferences
September 05, 2023 07:00 ET
|
Gritstone bio
EMERYVILLE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 16, 2023 16:30 ET
|
Gritstone bio
EMERYVILLE, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio and Genevant Sciences Announce Option and License Agreement
August 15, 2023 07:00 ET
|
Gritstone bio
Agreement provides nonexclusive access to Genevant’s leading LNP technology for use with Gritstone bio’s self-amplifying RNA technology in wide array of infectious disease vaccines Multi-year,...
Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
August 09, 2023 16:05 ET
|
Gritstone bio
-- Enrollment completed in Phase 2 portion of Phase 2/3 study evaluating GRANITE (personalized cancer vaccine [PCV]) in first-line metastatic microsatellite-stable colorectal cancer (MSS-CRC);...